Related Experiment Video

Updated: Feb 23, 2026

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

1.3K

Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure

Francesco Clemenza1, Serge Masson2, Pier Giulio Conaldi3

  • 1Heart Failure Unit, ISMETT.

Circulation Journal : Official Journal of the Japanese Circulation Society
|September 1, 2017
PubMed

Insights

Galectin-3 (Gal-3) is a prognostic biomarker in heart failure. While Gal-3 levels increased over six months and correlated with outcomes, the mineralocorticoid receptor antagonist canrenone did not alter this association.

Area of Science:

  • Cardiology
  • Biomarkers
  • Pharmacology

Background:

  • Galectin-3 (Gal-3) is implicated in collagen deposition and inflammation.
  • Gal-3 serves as a prognostic biomarker in heart failure (HF).

Purpose of the Study:

  • To evaluate the treatment effect of canrenone on clinical outcomes in mild HF patients.
  • To assess the association between Gal-3 levels, fibrosis markers, and clinical outcomes.
  • To determine if baseline biomarker concentrations influence canrenone's effect on outcomes.

Main Methods:

  • Serial measurement of Gal-3 and other fibrosis/cardiac stress markers in 413 mild HF patients.
  • Randomization to either mineralocorticoid receptor antagonist canrenone or placebo.
  • Correlation analysis between biomarkers, treatment, and clinical endpoints over 6 months.

Main Results:

  • Gal-3 levels showed a slight increase over 6 months in both canrenone and placebo groups.
  • Elevated Gal-3 levels were associated with adverse clinical endpoints.
  • Canrenone's effect on clinical outcomes was independent of baseline Gal-3 or other fibrosis/stress markers.

Conclusions:

  • Galectin-3 demonstrates prognostic value in mild heart failure.
  • Canrenone treatment efficacy in mild HF is not modulated by baseline fibrosis or cardiac stress biomarkers.
  • Further research may explore Gal-3's role in HF progression and therapeutic interventions.
Abstract

Keywords:
B-type natriuretic peptideClinical trialsGalectin-3Heart failureMineralocorticoid receptor antagonist

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.6K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.3K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
399
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K